— To generate a panel of antibodies against ZIKV, we serially infected Irf3/ mice 30 days apart with ZIKV MR-766 (Uganda, 1947) and ZIKV H/PF/2013 (French Polynesia, 2013). Irf3/ mice were used instead of wild-type (WT) mice, because ZIKV strains are deficient in evading type I interferon-mediated imm…
— Target: Major Histocompatibility Complex, Class 1-Related Protein
Notes: Clone available is 26.5
Publication: Evidence for MR1 Antigen Presentation to Mucosal-associated Invariant T Cells
—
Disease indication – Osteoporosis, skeletal metastasis, and potentially rheumatoid arthritis, psoriasis, acute myeloid leukemia, and breast cancer
Drug format – Engineered Protein
Research stage and Preliminary data – Proof of concept in vitro and in vivo
Target – Receptor A…
— Researchers in Prof. Daved Fremont’s laboratory have identified two potent, soluble proteins that could prevent damage to transplanted organs and potentially treat other autoimmune and inflammatory diseases by evading the immune response instigated by chemokines.
In organ transplants, chemoki…
— Disease Indications
Drug type: Biologic – engineered protein
Drug class: First in class
Technology:
A recombinant fusion protein that depletes B cells in the recipient that are specific to the donor HLA. The fusion protein offers a targeted therapy for antibody-mediated rejection in the …
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
